---
title: "Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291851772.md"
description: "Halper Sadeh LLC is investigating Element Solutions, InMed Pharmaceuticals, Huntsman Corporation, and Olin Corporation for potential breaches of fiduciary duties. The firm questions whether shareholders are receiving fair deals in proposed mergers and sales, citing concerns that insiders may benefit disproportionately and terms might limit competing offers. Shareholders are encouraged to contact the firm to discuss their legal rights and options regarding these transactions."
datetime: "2026-07-06T23:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291851772.md)
  - [en](https://longbridge.com/en/news/291851772.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291851772.md)
---

# Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?

**_Insiders may stand to receive substantial financial benefits not available to ordinary shareholders._**

**_The proposed transactions may contain terms that could limit superior competing offers._**

**_Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses._**

NEW YORK, July 6, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

**Element Solutions Inc ()'s** sale to Solstice Advanced Materials, Inc. for $10.00 in cash and 0.500 shares of Solstice common stock for each Element share. Upon closing of the Proposed Transaction, Element shareholders are expected to own approximately 44% of the combined company. **If you are an Element shareholder,** **click here to learn more about your rights and options****.**

**InMed Pharmaceuticals, Inc. ()'s** merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately 1.51% of the combined company. **If you are an InMed shareholder,** **click here to learn more about your legal rights and options**.

**Huntsman Corporation ()'s** sale to Olin Corporation for 0.5476 shares of Olin for each share of Huntsman. **If you are a Huntsman shareholder,** **click here to learn more about your legal rights and options**.

**Olin Corporation ()'s** merger with Huntsman Corporation. Upon closing of the proposed transaction, Olin shareholders will own approximately 54.5% of the combined company. **If you are an Olin shareholder,** **click here to learn more about your rights and options****.**

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLC

Daniel Sadeh, Esq.

Zachary Halper, Esq.

One World Trade Center

85th Floor

New York, NY 10007

(212) 763-0060

sadeh@halpersadeh.com

zhalper@halpersadeh.com

https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

### Related Stocks

- [HUN.US](https://longbridge.com/en/quote/HUN.US.md)
- [OLN.US](https://longbridge.com/en/quote/OLN.US.md)
- [ESI.US](https://longbridge.com/en/quote/ESI.US.md)
- [INM.US](https://longbridge.com/en/quote/INM.US.md)
- [SOLS.US](https://longbridge.com/en/quote/SOLS.US.md)
- [SOLSV.US](https://longbridge.com/en/quote/SOLSV.US.md)

## Related News & Research

- [Olin (NYSE:OLN) Hits New 12-Month Low  - What's Next?](https://longbridge.com/en/news/294576663.md)
- [Olin (NYSE:OLN) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS](https://longbridge.com/en/news/294565065.md)
- [Huntsman Q2 revenue beats analyst expectations on higher volumes and pricing](https://longbridge.com/en/news/294412204.md)
- [ESI: Record Q2 2026 revenue and EBITDA driven by Electronics and semiconductor strength](https://longbridge.com/en/news/293971579.md)
- [Integration Risks Loom Over Solstice Advanced Materials–Element Solutions Merger, Threatening Synergies and Financial Performance](https://longbridge.com/en/news/294575426.md)